Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient. Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC. Five immune checkpoint inhibitors were approved between 2016 and 2017 for first- or second-line intervention and two therapies with completely different mechanisms — a fibroblast growth factor receptor inhibitor and an antibody drug conjugate — were granted accelerated approval for metastatic UC in 2019.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicate an already complex condition. This activity will guide them in selecting and using these options.
Matthew Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Thomas Powles, MBBS, MRCP, MD
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Brian Rini, MD, FASCO
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with UC.
Upon completion of this educational activity, participants should be able to:
There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Matthew Galsky, MD
Consulting Fees: Genetech, AstraZeneca, Bristol Myers Squibb, Astellas, Seattle Genetics, Pfizer, EMD Serono, Merck
Thomas Powels, MD
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis, Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD
Research Funding to Institution: Aravive, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Dragonfly Therapeutics, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Mirati Therapeutics, Merck, Pfizer, Seattle Genetics, Surface Oncology, Taris
Consulting: Aravive, Alkermes, Arrowhead, Aveo, Bristol Myers Squibb, Compugen, Corvus, Eisai, GlaxoSmithKline, Genentech/Roche, Merck, Pfizer, Surface Oncology, Shionogi, Synthorx, 3DMedicines
Stock: PTC therapeutics
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
On the day of the program, you may access the event by going to any of the following links:
There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 0.75 AMA PRA Category 1 CME credit(s)TM. To do so, you must participate in the virtual live stream activity and complete the posttest and evaluation following the event. A statement of credit will be issued only upon submission of a completed activity evaluation form.